Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study.
Open Access
- 28 September 1998
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 158 (17), 1882-1886
- https://doi.org/10.1001/archinte.158.17.1882
Abstract
HYPERTENSION is well established as a risk factor for cardiovascular disease morbidity and mortality.1-3 Meta-analyses of several clinical trials4-7 on hypertension have demonstrated reductions in cardiovascular mortality in response to treatment with diuretics and β-blockers alone or in combination.Keywords
This publication has 12 references indexed in Scilit:
- An Investigation of Coronary Heart Disease in Families: The Framingham Offspring StudyAmerican Journal of Epidemiology, 2017
- Calcium antagonists and mortality in patients with coronary artery disease: A Cohort study of 11,575 patientsJournal of the American College of Cardiology, 1996
- Nifedipine: Dose related increase in mortality in patients with coronary heart diseaseThe Journal of Emergency Medicine, 1996
- Calcium Antagonists in Coronary Artery Disease and HypertensionCirculation, 1995
- Nifedipine in Ischemic Heart DiseaseCirculation, 1995
- Current status of calcium channel blockersCurrent Problems in Cardiology, 1994
- Hemodynamic comparison of two nifedipine formulations in patients with essential hypertensionThe American Journal of Cardiology, 1991
- Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial.Circulation, 1988
- Mechanism of Action of Calcium-Channel-Blocking AgentsNew England Journal of Medicine, 1982
- AN APPROACH TO LONGITUDINAL STUDIES IN A COMMUNITY: THE FRAMINGHAM STUDYAnnals of the New York Academy of Sciences, 1963